Skip to main content

Osteoporotic Fracture

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
LYN101Phase 11 trial
Active Trials
NCT07178327Enrolling By Invitation44Est. Sep 2027
Avenue Therapeutics
Avenue TherapeuticsFL - Bay Harbor Islands
1 program
9 days spa residential programN/A1 trial
Active Trials
NCT03570008Unknown90Est. Mar 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BiocorpLYN101
Avenue Therapeutics9 days spa residential program

Clinical Trials (2)

Total enrollment: 134 patients across 2 trials

Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101

Start: Sep 2025Est. completion: Sep 202744 patients
Phase 1Enrolling By Invitation
NCT03570008Avenue Therapeutics9 days spa residential program

Preventing the Risk of Osteoporotic Fracture in Premenopausal Women by a Spa Residential Physical Activity Program

Start: Mar 2017Est. completion: Mar 202190 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.